Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 12/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.47 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3615108 | 0.94 | IKBKB (0.53) | IKBKBCHEK1MAP3K7ADRB2ALOX15 | |
| SCHEMBL3608050 | 0.87 | CHEK1 (0.63) | IKBKBCHEK1 | |
| SCHEMBL3615111 | 0.82 | CHEK1 (0.52) | IKBKBCHEK1MAP3K7KDM4E | |
| SCHEMBL3608243 | 0.80 | IKBKB (0.55) | IKBKBCHEK1MAP3K7 | |
| SCHEMBL3610863 | 0.80 | IKBKB (0.60) | IKBKBCHEK1MAP3K7 | |
| SCHEMBL3607420 | 0.79 | CHEK1 (0.74) | IKBKBCHEK1MAP3K7 | |
| SCHEMBL3619297 | 0.78 | IKBKB (0.50) | IKBKBCHEK1MAP3K7 | |
| SCHEMBL3612210 | 0.77 | CHEK1 (0.65) | IKBKBCHEK1MAP3K7 | |
| SCHEMBL3612524 | 0.76 | IKBKB (0.63) | IKBKBCHEK1MAP3K7KDM4E | |
| SCHEMBL3614907 | 0.75 | MAP3K7 (0.54) | IKBKBCHEK1MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029754-A1 | THIOPHENE-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SW) | 2010-02-04 | — | — | US | disclosed |
| US-7572826-B2 | Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-20060058522-A1 | Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058522-A1 | Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 | NFKBIA, RELA, IKBKE | IKBKB 5/4885CHEK1 487/4885MAP3K7 129/4885 |
| US-20100029754-A1 | THIOPHENE-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | NFKBIA, RELA, IKBKE | IKBKB 5/4885CHEK1 487/4885MAP3K7 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.